Down syndrome and Alzheimer's disease: Common pathways, common goals

Alzheimer's and Dementia

Volumn 11, Issue 6, 2015, Pages 700-709

  Hartley, Dean ^a   Blumenthal, Thomas ^b   Carrillo, Maria ^a   DiPaolo, Gilbert ^c   Esralew, Lucille ^d   Gardiner, Katheleen ^b,e   Granholm, Ann Charlotte ^f   Iqbal, Khalid ^g   Krams, Michael ^h   Lemere, Cynthia ⁱ   Lott, Ira ^j   Mobley, William ^k   Ness, Seth ^h   Nixon, Ralph ^l   Potter, Huntington ^b,m   Reeves, Roger ⁿ   Sabbagh, Marwan ^o   Silverman, Wayne ^n,p   Tycko, Benjamin ^c   Whitten, Michelle ^q   Wisniewski, Thomas ^r   more..

^a ALZHEIMER'S ASSOCIATION   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^d Trinitas Regional Medical Center   (United States)

^e Nutrition Obesity Research Center at the University of Colorado   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l NEW YORK UNIVERSITY   (United States)

^m UNIVERSITY OF COLORADO   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o BANNER HEALTH   (United States)

^p KENNEDY KRIEGER INSTITUTE   (United States)

^q Global Down Syndrome Foundation   (United States)

^r NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

ADNI; Alzheimer's disease; Amyloid precursor protein; Animal models; Beta amyloid; Biomarkers; Clinical trials; Cognitive assessment; Dementia; Down syndrome; Drug discovery; DS Connect; Neuroimaging; Neuroinflammation; Tau; Trisomy 21; Ts65Dn; Workshop

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ATOMOXETINE; BETA SECRETASE; BRAIN DERIVED NEUROTROPHIC FACTOR; DROXIDOPA; EPIGALLOCATECHIN GALLATE; FLUORODEOXYGLUCOSE F 18; GAMMA SECRETASE; INOSITOL; MEMANTINE; NERVE GROWTH FACTOR; NICOTINE; PROTEIN S100B;

ALZHEIMER DISEASE; ASTROCYTOSIS; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL (TOPIC); COGNITION ASSESSMENT; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEMENTIA; DIETARY INTAKE; DOWN SYNDROME; ENDOCYTOSIS; EXERCISE; GENETIC RISK; HUMAN; INTELLECTUAL IMPAIRMENT; LIFESTYLE; LONG TERM POTENTIATION; MOUSE MODEL; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN METABOLISM; RESEARCH PRIORITY; REVIEW; TRISOMY 21; VASCULAR AMYLOIDOSIS; WORKSHOP; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; NEUROPSYCHOLOGICAL TEST; ORGANIZATION; PATHOLOGY; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DISEASE MODELS, ANIMAL; DOWN SYNDROME; DRUG DISCOVERY; HUMANS; NEUROPSYCHOLOGICAL TESTS;

EID: 84931070277     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.10.007     Document Type: Article

References (79)

1. D.M. Wilcock, and W.S. Griffin Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis J Neuroinflammation 10 2013 84
2. F. Lai, and R.S. Williams A prospective study of Alzheimer's disease in Down syndrome Arch Neurol 46 1989 849 853
3. K. Wisniewski, H. Wisniewski, and G. Wen Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome Ann Neurol 17 1985 278 282
4. D.M. Mann The pathological association between Down syndrome and Alzheimer disease Mech Ageing Dev 43 1988 99 136
5. B. Rumble, R. Retallack, C. Hilbich, G. Simms, G. Multhaup, R. Martins, et al. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease N Engl J Med 320 1989 1446 1452
6. C.A. Lemere, J.K. Blusztajn, H. Yamaguchi, T. Wisniewski, T.C. Saido, and D.J. Selkoe Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation Neurobiol Dis 3 1996 16 32
7. J.L. Frost, K.X. Le, H. Cynis, E. Ekpo, M. Kleinschmidt, R.M. Palmour, et al. Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models Am J Pathol 183 2013 369 381
8. B.L. Handen, A.D. Cohen, U. Channamalappa, P. Bulova, S.A. Cannon, W.I. Cohen, et al. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B Alzheimers Dement 8 2012 496 501
9. L.D. Nelson, P. Siddarth, V. Kepe, K.E. Scheibel, S.C. Huang, J.R. Barrio, et al. Positron emission tomography of brain beta-amyloid and tau levels in adults with Down syndrome Arch Neurol 68 2011 768 774
10. B.T. Hyman, H.L. West, G.W. Rebeck, F. Lai, and D.M. Mann Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype Arch Neurol 52 1995 373 378
11. P.R. Hof, C. Bouras, D.P. Perl, L. Sparks, N. Mehta, and J.H. Morrison Age-related distribution of neuropathological changes in the cerebral cortex of patients with Down's syndrome Arch Neurol 52 1995 379 391
12. D.M.A. Mann, P.O. Yates, B. Marcyniuk, and C.R. Ravindra Loss of neurones from cortical and subcortical areas in Down's syndrome patients at middle age J Neurol Sci 80 1987 79 89
13. I.T. Lott, and E. Head Down syndrome and Alzheimer's disease: a link between development and aging Ment Retard Dev Disabil Res Rev 7 2001 172 178
14. W.B. Zigman, and I.T. Lott Alzheimer's disease in Down syndrome: neurobiology and risk Ment Retard Dev Disabil Res Rev 13 2007 237 246
15. W.B. Zigman, D.A. Devenny, S.J. Krinsky-McHale, E.C. Jenkins, T.K. Urv, J. Wegiel, et al. Alzheimer's disease in adults with down syndrome Int Rev Res Ment Retard 36 2008 103 145
16. D.M. Wilcock Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease Curr Gerontol Geriatr Res 2012 2012 170276
17. E. Head, W. Silverman, D. Patterson, and I.T. Lott Aging and Down syndrome Curr Gerontol Geriatr Res 2012 2012 412536
18. A. Rovelet-Lecrux, D. Hannequin, G. Raux, N. Le Meur, A. Laquerriere, A. Vital, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy Nat Genet 38 2006 24 26
19. J. Theuns, N. Brouwers, S. Engelborghs, K. Sleegers, V. Bogaerts, E. Corsmit, et al. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease Am J Hum Genet 78 2006 936 946
20. H. Lv, L. Jia, and J. Jia Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer's disease Neurobiol Aging 29 2008 194 202
21. V.P. Prasher, M.J. Farrer, A.M. Kessling, E.M. Fisher, R.J. West, P.C. Barber, et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome Ann Neurol 43 1998 380 383
22. A.M. Cataldo, C.M. Peterhoff, J.C. Troncoso, T. Gomez-Isla, B.T. Hyman, and R.A. Nixon Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations Am J Pathol 157 2000 277 286
23. A. Salehi, J.D. Delcroix, P.V. Belichenko, K. Zhan, C. Wu, J.S. Valletta, et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration Neuron 51 2006 29 42
24. J.P. Lockrow, A.M. Fortress, and A.C. Granholm Age-related neurodegeneration and memory loss in Down syndrome Curr Gerontol Geriatr Res 2012 2012 463909
25. A.C. Granholm, L.A. Sanders, and L.S. Crnic Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome Exp Neurol 161 2000 647 663
26. M.F. Iulita, S. Do Carmo, A.K. Ower, A.M. Fortress, L.F. Aguilar, M. Hanna, et al. Nerve growth factor metabolic dysfunction in Down's syndrome brains Brain 137 2014 860 872
27. S.D. Ginsberg, M.J. Alldred, S.E. Counts, A.M. Cataldo, R.L. Neve, Y. Jiang, et al. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression Biol Psychiatry 68 2010 885 893
28. Y. Jiang, K.A. Mullaney, C.M. Peterhoff, S. Che, S.D. Schmidt, A. Boyer-Boiteau, et al. Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition Proc Natl Acad Sci U S A 107 2010 1630 1635
29. V.P. Prasher, S.G. Sajith, S.D. Rees, A. Patel, S. Tewari, N. Schupf, et al. Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down syndrome Int J Geriatr Psychiatry 23 2008 1134 1140
30. N. Schupf, D. Kapell, J.H. Lee, W. Zigman, B. Canto, B. Tycko, et al. Onset of dementia is associated with apolipoprotein E epsilon4 in Down's syndrome Ann Neurol 40 1996 799 801
31. M.C. Royston, D. Mann, S. Pickering-Brown, F. Owen, R. Perry, R. Raghavan, et al. Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down's syndrome from dementia Neuroreport 5 1994 2583 2585
32. W.K. Dowjat, T. Adayev, I. Kuchna, K. Nowicki, S. Palminiello, Y.W. Hwang, et al. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome Neurosci Lett 413 2007 77 81
33. W. Qian, H. Liang, J. Shi, N. Jin, I. Grundke-Iqbal, K. Iqbal, et al. Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A Nucleic Acids Res 39 2011 6161 6171
34. F. Liu, Z. Liang, J. Wegiel, Y.W. Hwang, K. Iqbal, I. Grundke-Iqbal, et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome FASEB J 22 2008 3224 3233
35. J. Wegiel, W. Kaczmarski, M. Barua, I. Kuchna, K. Nowicki, K.C. Wang, et al. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome J Neuropathol Exp Neurol 70 2011 36 50
36. S.R. Ryoo, H.J. Cho, H.W. Lee, H.K. Jeong, C. Radnaabazar, Y.S. Kim, et al. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease J Neurochem 104 2008 1333 1344
37. W. Becker, U. Soppa, and F.J. Tejedor DYRK1A: a potential drug target for multiple Down syndrome neuropathologies CNS Neurol Disord Drug Targets 13 2014 26 33
38. S.V. Voronov, S.G. Frere, S. Giovedi, E.A. Pollina, C. Borel, H. Zhang, et al. Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndrome Proc Natl Acad Sci U S A 105 2008 9415 9420
39. J.C. Cossec, J. Lavaur, D.E. Berman, I. Rivals, A. Hoischen, S. Stora, et al. Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes Hum Mol Genet 21 2012 3156 3172
40. D.E. Berman, C. Dall'Armi, S.V. Voronov, L.B. McIntire, H. Zhang, A.Z. Moore, et al. Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism Nat Neurosci 11 2008 547 554
41. W.S. Griffin, J.G. Sheng, J.E. McKenzie, M.C. Royston, S.M. Gentleman, R.A. Brumback, et al. Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis Neurobiol Aging 19 1998 401 405
42. H. Potter, and T. Wisniewski Apolipoprotein e: essential catalyst of the Alzheimer amyloid cascade Int J Alzheimers Dis 2012 2012 489428
43. A. Letourneau, F.A. Santoni, X. Bonilla, M.R. Sailani, D. Gonzalez, J. Kind, et al. Domains of genome-wide gene expression dysregulation in Down's syndrome Nature 508 2014 345 350
44. C.L. Hunter, D. Bachman, and A.C. Granholm Minocycline prevents cholinergic loss in a mouse model of Down's syndrome Ann Neurol 56 2004 675 688
45. S.E. Stoltzner, T.J. Grenfell, C. Mori, K.E. Wisniewski, T.M. Wisniewski, D.J. Selkoe, et al. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease Am J Pathol 156 2000 489 499
46. K. Kerkel, N. Schupf, K. Hatta, D. Pang, M. Salas, A. Kratz, et al. Altered DNA methylation in leukocytes with trisomy 21 PLoS Genet 6 2010 e1001212
47. L.N. Geller, and H. Potter Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease Neurobiol Dis 6 1999 167 179
48. T. Arendt, M.K. Bruckner, B. Mosch, and A. Losche Selective cell death of hyperploid neurons in Alzheimer's disease Am J Pathol 177 2010 15 20
49. S.I. Borysov, A. Granic, J. Padmanabhan, C.E. Walczak, and H. Potter Alzheimer Abeta disrupts the mitotic spindle and directly inhibits mitotic microtubule motors Cell Cycle 10 2011 1397 1410
50. J. Blanchard, S. Bolognin, M.O. Chohan, A. Rabe, K. Iqbal, and I. Grundke-Iqbal Rescue of synaptic failure and alleviation of learning and memory impairments in a trisomic mouse model of down syndrome J Neuropathol Exp Neurol 70 2011 1070 1079
51. X. Sturgeon, and K.J. Gardiner Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions Mamm Genome 22 2011 261 271
52. P.V. Belichenko, A.M. Kleschevnikov, A. Salehi, C.J. Epstein, and W.C. Mobley Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships J Comp Neurol 504 2007 329 345
53. J. Lockrow, H. Boger, G. Gerhardt, G. Aston-Jones, D. Bachman, and A.C. Granholm A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model J Alzheimers Dis 23 2011 471 489
54. J.T. Richtsmeier, L.L. Baxter, and R.H. Reeves Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice Dev Dyn 217 2000 137 145
55. X. Sturgeon, T. Le, M.M. Ahmed, and K.J. Gardiner Pathways to cognitive deficits in Down syndrome Prog Brain Res 197 2012 73 100
56. M.M. Ahmed, A.R. Dhanasekaran, S. Tong, F.K. Wiseman, E.M. Fisher, V.L. Tybulewicz, et al. Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain Hum Mol Genet 22 2013 1709 1724
57. K. Gardiner, and A.C. Costa The proteins of human chromosome 21 Am J Med Genet C Semin Med Genet 142c 2006 196 205
58. K.J. Gardiner Molecular basis of pharmacotherapies for cognition in Down syndrome Trends Pharmacol Sci 31 2010 66 73
59. A.M. Kleschevnikov, P.V. Belichenko, A. Salehi, and C. Wu Discoveries in Down syndrome: moving basic science to clinical care Prog Brain Res 197 2012 199 221
60. N. Rueda, J. Florez, and C. Martinez-Cue Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities Neural Plast 2012 2012 584071
61. T. Yu, Z. Li, Z. Jia, S.J. Clapcote, C. Liu, S. Li, et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions Hum Mol Genet 19 2010 2780 2791
62. I.T. Lott, and M. Dierssen Cognitive deficits and associated neurological complications in individuals with Down's syndrome Lancet Neurol 9 2010 623 633
63. J.O. Edgin, G.M. Mason, M.J. Allman, G.T. Capone, I. Deleon, C. Maslen, et al. Development and validation of the Arizona Cognitive Test Battery for Down syndrome J Neurodev Disord 2 2010 149 164
64. J. Landt, J.C. D'Abrera, A.J. Holland, F.I. Aigbirhio, T.D. Fryer, R. Canales, et al. Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar beta-amyloid in adults with down syndrome: safety, acceptability, and feasibility Arch Neurol 68 2011 890 896
65. M.N. Sabbagh, A. Fleisher, K. Chen, J. Rogers, C. Berk, E. Reiman, et al. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease Arch Neurol 68 2011 1461 1466
66. I.T. Lott Neurological phenotypes for Down syndrome across the life span Prog Brain Res 197 2012 101 121
67. S.J. Teipel, and H. Hampel Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease Behav Genet 36 2006 405 415
68. D. Mullins, E. Daly, A. Simmons, F. Beacher, C.M. Foy, S. Lovestone, et al. Dementia in Down's syndrome: an MRI comparison with Alzheimer's disease in the general population J Neurodev Disord 5 2013 19
69. E.C. Jenkins, L. Ye, M. Velinov, S.J. Krinsky-McHale, W.B. Zigman, N. Schupf, et al. Mild cognitive impairment identified in older individuals with Down syndrome by reduced telomere signal numbers and shorter telomeres measured in microns Am J Med Genet B Neuropsychiatr Genet 159b 2012 598 604
70. N. Schupf, W.B. Zigman, M.X. Tang, D. Pang, R. Mayeux, P. Mehta, et al. Change in plasma Ass peptides and onset of dementia in adults with Down syndrome Neurology 75 2010 1639 1644
71. L. Gold, N. Janjic, T. Jarvis, D. Schneider, J.J. Walker, S.K. Wilcox, et al. Aptamers and the RNA world, past and present Cold Spring Harb Perspect Biol 4 2012
72. S. Ness, M. Rafii, P. Aisen, M. Krams, W. Silverman, and H. Manji Down's syndrome and Alzheimer's disease: towards secondary prevention Nat Rev Drug Discov 11 2012 655 656
73. M.C. Carrillo, L.J. Bain, G.B. Frisoni, and M.W. Weiner Worldwide Alzheimer's disease neuroimaging initiative Alzheimers Dement 8 2012 337 342
74. S. Ekstein, B. Glick, M. Weill, B. Kay, and I. Berger Down syndrome and attention-deficit/hyperactivity disorder (ADHD) J Child Neurol 26 2011 1290 1295
75. A. Bari, and T.W. Robbins Inhibition and impulsivity: behavioral and neural basis of response control Prog Neurobiol 108 2013 44 79
76. L. Trillo, D. Das, W. Hsieh, B. Medina, S. Moghadam, B. Lin, et al. Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care Neurosci Biobehav Rev 37 2013 1363 1379
77. H. Scholtzova, R.J. Kascsak, K.A. Bates, A. Boutajangout, D.J. Kerr, H.C. Meeker, et al. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology J Neurosci 29 2009 1846 1854
78. M.C. Carrillo, H.R. Brashear, V. Logovinsky, J.M. Ryan, H.H. Feldman, E.R. Siemers, et al. Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease Alzheimers Dement 9 2013 123 131.e1
79. L.G. Reinholdt, Y. Ding, G.J. Gilbert, A. Czechanski, J.P. Solzak, R.J. Roper, et al. Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn Mamm Genome 22 2011 685 691